ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tegafur

Also written as “S-1”, “S-1/Cisplatin” and “S-1, Irinotecan, Bevacizumab”.

Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Renal Insufficiency, led by 4 companies.

Drug pageTegafur: every studyAll 189 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 30, 200525 company-led studies, 1 open or runningNext primary completion: Jun 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka190 open or runningphase 3since Jun 30, 2005Jun 30, 2005none ahead
TTY Biopharmits history only40 open or runningphase 2since Mar 26, 2015Jun 4, 2013none ahead
Innovent Biologicsits history only11 open or runningphase 2since Mar 16, 2026Mar 16, 2026Jun 30, 2030phase 2 · NCT07483567
Sanofiits history only10 open or runningphase 3since Jan 16, 2008Jan 16, 2008none ahead

Also a collaborator on its studies: Quintiles, United BioSource and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2005First study: phase 3 study in Stomach NeoplasmsFirst studyNCT00400179 · 1,053 enrolled · United States, Canada
  2. Sep 7, 20053 phase 3 studies in Stomach NeoplasmsNCT00150670, NCT00152217, NCT00202969
  3. Jan 30, 2006Phase 3 study in Colorectal NeoplasmsNCT00284258 · 426 enrolled · Japan
  4. Nov 8, 20063 phase 1 studiesNCT00398424, NCT00398307, NCT00400023
  5. Jul 6, 2007Phase 3 study in Pancreatic NeoplasmsNCT00498225 · 834 enrolled · Japan, Taiwan
  6. Dec 5, 20073 phase 2 studiesNCT00569790, NCT00569699, NCT00569335
  7. Mar 31, 20084 phase 2 studiesNCT00652561, NCT00652054, NCT00651833 and 1 more
  8. Oct 9, 2008Phase 3 study in Uterine Cervical NeoplasmsNCT00770874 · 375 enrolled · Japan, Korea, Republic of, Taiwan
  9. Apr 30, 2009Phase 2 study in Colorectal NeoplasmsNCT00891332 · 73 enrolled · China, Japan
  10. Jan 26, 2011Phase 3 study in Stomach NeoplasmsNCT01285557 · 361 enrolled · United States, Argentina, Belgium and more

TargetBeta

TYMS →read by rule
“RNA inhibitor; Thymidylate synthase inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
FluorouracilruleSanofiphase 482

Studies

All 19 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01285557Stomach Neoplasms · United States, Argentina, Belgium and more3TerminatedAug 15, 2014361
NCT00891332Colorectal Neoplasms · China, Japan2CompletedJul 201173
NCT00770874Uterine Cervical Neoplasms · Japan, Korea, Republic of, Taiwan3CompletedDec 2015375
NCT00652561Advanced Non-Small Cell Lung Cancer2CompletedNov 200757
NCT00652054Pancreatic Neoplasms2CompletedJun 200739
NCT00651833Advanced Non-Small Cell Lung Cancer2CompletedOct 200660
NCT00651742Pancreatic Neoplasms2CompletedJul 8, 200828
NCT00569790Colorectal Neoplasms · Japan2CompletedMar 201053
NCT00569699Colorectal Neoplasms · Japan2CompletedMar 201156
NCT00569335Colonic Neoplasms · Japan2CompletedMar 201052
NCT00498225Pancreatic Neoplasms · Japan, Taiwan3CompletedJul 2011834
NCT00400023Neoplasms · United States1CompletedMay 200712
NCT00398424Impaired Hepatic Function · United States1CompletedNov 200824
NCT00398307Renal Insufficiency · United States1CompletedSep 201024
NCT00284258Colorectal Neoplasms · Japan3CompletedJul 2010426
NCT00202969Stomach Neoplasms · China3CompletedJan 2007180
NCT00152217Stomach Neoplasms · Japan3CompletedMay 20071,000
NCT00150670Stomach Neoplasms · Japan3CompletedDec 2006300
NCT00400179Stomach Neoplasms · United States, Canada3CompletedMar 20081,053

How it is read

Names in the registry

  • “S-1”, 8 entries
  • “S-1/Cisplatin”, 3 entries
  • “S-1, Irinotecan, Bevacizumab”, 2 entries
  • “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
  • “S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.